The electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, were investigated in a randomized, placebo-controlled, double-blind study, and efficacy was evaluated. Ten post-myocardial infarction patients with complex ventricular arrhythmias were included and received, in randomized order on consecutive days, 4.5 mg (12.8 mumol) of almokalant or placebo intravenously over 10 minutes. One patient received infusion at a higher, rate and developed self-terminating torsades de pointes. In the remaining 9 patients the corrected QT interval increased significantly- At the end of placebo infusion the corrected QT was 445 +/- 18 ms and after almokalant 548 +/- 53 ms (p = 0.0015). The signal-averaged electrocar...
Over the past decade, various studies have demonstrated that class I antiarrhythmic drugs should be ...
Department of Pharmacology and Clinical Pharmacology, State University of Medicine and Pharmacy “Nic...
In an open-label study, electrophysiology and pharmacokinetics of TYB-3823, a new antiarrhythmic com...
The electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic,...
The interest in class III drugs has increased over the last decades as being potent antiarrhythmic a...
Ventricular arrhythmias remain a major problem, in particular in patients with left ventricular dysf...
The electrophysiologic effects of intravenously administered almokalant, a new class III antiarrhyth...
The treatment of cardiac arrhythmias has undergone a sea change with the advent of catheter ablative...
Antiarrhythmic drugs have specific electrophysiologic actions that alter cardiac conductions. These ...
The antiarrhythmic efficacy and safety of intravenous recainam, a newly synthesized compound display...
In the search for new and more effective antiarrhythmic agents a great deal of effort has been expe...
Despite advances in catheter ablation techniques anddevice-based therapies for cardiac arrhythmias, ...
Arrhythmias are abnormalities of cardiac rate or rhythm occurring for a variety of reasons. They are...
In an open-label study, electrophysiology and pharmacokinetics of TYB-3823, a new antiarrhythmic com...
Over the past decade, various studies have demonstrated that class I antiarrhythmic drugs should be ...
Department of Pharmacology and Clinical Pharmacology, State University of Medicine and Pharmacy “Nic...
In an open-label study, electrophysiology and pharmacokinetics of TYB-3823, a new antiarrhythmic com...
The electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic,...
The interest in class III drugs has increased over the last decades as being potent antiarrhythmic a...
Ventricular arrhythmias remain a major problem, in particular in patients with left ventricular dysf...
The electrophysiologic effects of intravenously administered almokalant, a new class III antiarrhyth...
The treatment of cardiac arrhythmias has undergone a sea change with the advent of catheter ablative...
Antiarrhythmic drugs have specific electrophysiologic actions that alter cardiac conductions. These ...
The antiarrhythmic efficacy and safety of intravenous recainam, a newly synthesized compound display...
In the search for new and more effective antiarrhythmic agents a great deal of effort has been expe...
Despite advances in catheter ablation techniques anddevice-based therapies for cardiac arrhythmias, ...
Arrhythmias are abnormalities of cardiac rate or rhythm occurring for a variety of reasons. They are...
In an open-label study, electrophysiology and pharmacokinetics of TYB-3823, a new antiarrhythmic com...
Over the past decade, various studies have demonstrated that class I antiarrhythmic drugs should be ...
Department of Pharmacology and Clinical Pharmacology, State University of Medicine and Pharmacy “Nic...
In an open-label study, electrophysiology and pharmacokinetics of TYB-3823, a new antiarrhythmic com...